在晚期癌症中进行综合基因组分析的广泛技术评估的因素,系统审查

L F van Schaik1, E G Engelhardt2, E A Wilthagen3

  • 1Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90103, Amsterdam 1006 BE, the Netherlands; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.

概括

综合基因组分析 (CGP) 识别了许多目标,但报销决策是复杂的. 这项研究确定了超越成本和临床益处的五个关键因素,以改善CGP技术评估.